Jacobs Levy Equity Management
DYN icon

Jacobs Levy Equity Management’s Dyne Therapeutics DYN Stock Holding History

Jacobs Levy Equity Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-729,606
Closed -$9.23M – 962
2025
Q3 		$9.23M Buy
+729,606
New +$8.32M 0.04% 313
2023
Q3 		– Sell
-24,279
Closed -$273K – 988
2023
Q2 		$273K Sell
24,279
-204,542
-89% -$2.41M ﹤0.01% 891
2023
Q1 		$2.64M Sell
228,821
-61,172
-21% -$794K 0.02% 525
2022
Q4 		$3.36M Buy
289,993
+68,945
+31% +$798K 0.02% 464
2022
Q3 		$2.81M Buy
+221,048
New +$2.53M 0.02% 496

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Jacobs Levy Equity Management's DYN Position: Q4 2025 in Review

Jacobs Levy Equity Management sold out of Dyne Therapeutics (DYN) in Q4 2025, closing a stake of 729,606 shares — an estimated $9.23M sold.

Jacobs Levy Equity Management first reported a position in DYN in Q3 2022 and held it in 5 quarters. The position peaked at $9.23M in Q3 2025. 232 funds tracked by Wall St. Rank hold DYN as of Q4 2025.

  • Jacobs Levy Equity Management reported no remaining Dyne Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 729,606 Dyne Therapeutics shares in Q4 2025, an estimated $9.23M.
  • Jacobs Levy Equity Management first reported a position in Dyne Therapeutics in Q3 2022 and held it in 5 quarters.
  • Jacobs Levy Equity Management's Dyne Therapeutics position peaked at $9.23M in Q3 2025.
  • 232 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2025, filed 13 Feb 2026.